Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
IPO Year: 2013
Exchange: NASDAQ
Website: kamada.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/21/2025 | $15.00 | Buy | The Benchmark Company |
| 7/3/2024 | $18.00 | Buy | Stifel |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00
Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00
Fastest customizable press release news feed in the world
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho
Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub
REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the first patient was enrolled into an investigator-initiated post-marketing clinical trial of CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) to prevent late Cytomegalovirus ("CMV") infection, a common post-transplant infectious complication that remains an unaddressed medical need, despite recent advances in anti-viral drug therapies. The study, titled "Strategic H
REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties
REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025. Mr. London is scheduled to present at 9:20 a.m. Eastern Time on Wednesday, November 12, 2025. In addition to the presentation, Mr. London will be available for one-on-one investor meetings throughout the
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Mr. London is scheduled to present at the 2025 Wells Fargo Healthcare Conference at 3:45 p.m. Eastern Time on Wednesday, September 3, 2025. In addition to the presentation, Mr. London will be available for one-on-one investor
First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of Revenues; Second Quarter Adjusted EBITDA of $10.9 Million, up 20% Year-over-YearRobust First Half Results and Positive Outlook for Remainder of 2025 Support Increased Adjusted EBITDA Guidance to $40 Million-$44 Million, and Reiteration of Full-Year Revenue Guidance of $178 Million-$182 MillionAnnounced FDA Approval of its Plasma Collection Center in Houston, Texas, which is Now Cleared to Commence Commercial Sales Company Continues to Focus o
Houston Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full CapacityCenter is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the Largest Sites for Specialty Plasma Collection in the U.S. REHOVOT, Israel, and HOBOKEN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a le
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2025, prior to the open of the U.S. financial markets on Wednesday, August 13, 2025. Kamada management will host an investment community conference call on Wednesday, August 13, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties ma
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and based on its assessment, the global availability of its products is not expected to be interrupted. "While events in the Middle East are evolving, the operations and ongoing manufacturing of our products continue as planned
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K/A - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
6-K - KAMADA LTD (0001567529) (Filer)
Live finance-specific insights
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho
Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub
REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties
First Half 2025 Total Revenues were $88.8 Million, up 11% Year-over-Year; Revenues for 2025 Second Quarter were $44.8 Million, up 5% Year-over-Year First Half 2025 Adjusted EBITDA of $22.5 Million, up 35% Year-over-Year and Representing 25% Margin of Revenues; Second Quarter Adjusted EBITDA of $10.9 Million, up 20% Year-over-YearRobust First Half Results and Positive Outlook for Remainder of 2025 Support Increased Adjusted EBITDA Guidance to $40 Million-$44 Million, and Reiteration of Full-Year Revenue Guidance of $178 Million-$182 MillionAnnounced FDA Approval of its Plasma Collection Center in Houston, Texas, which is Now Cleared to Commence Commercial Sales Company Continues to Focus o
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2025, prior to the open of the U.S. financial markets on Wednesday, August 13, 2025. Kamada management will host an investment community conference call on Wednesday, August 13, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties ma
Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm
REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in
REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines
Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA of $34.1 Million, Up 42% Year-over-Year, and a 21% Margin of RevenuesCash Provided by Operating Activities of $47.6 Million During 2024 Resulted in a Year-End Strong Cash Balance of $78.4 Million; Solid Financial Position to Accelerate Inorganic Growth Net Income for the Year was $14.5 Million, or $0.25 per Diluted Share, Up 75% Year-over-YearStrong Performance Positions Company for Double Digit Profitable Growth in Fiscal Year 2025; Reiterates 2025 Full-Year Revenue Guidance of $178 Million to $182 Million and Adjusted EBITDA of $38 Million to $42 MillionDeclares Spe
REHOVOT, Israel, and HOBOKEN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a special cash dividend of $0.20 (approximately NIS0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million). The special cash dividend will be payable on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. "Based on the Company's strong financial results for 2024 and its solid
Live Leadership Updates
Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op
REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h
This live feed shows all institutional transactions in real time.
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13D/A - KAMADA LTD (0001567529) (Subject)
SC 13D/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)
SC 13G/A - KAMADA LTD (0001567529) (Subject)